Company Filing History:
4 out of 2,078 
3 out of 76 Years Active: 2006-2012
Title: The Innovative Mind of Ehab Khalil
Introduction
Ehab Khalil is a distinguished inventor based in West Chester, PA, whose innovative contributions have led to an impressive portfolio of seven patents. His work primarily focuses on the field of pharmaceutical sciences, particularly concerning novel therapies for cell proliferative disorders.
Latest Patents
Among Ehab's latest inventions are groundbreaking triazolopyridazine compounds. These compounds are designed to serve as protein tyrosine kinase modulators, specifically inhibitors of c-Met. His patent describes the structural formula of these compounds, detailing the roles of various substituents. These compounds are pivotal in reducing or inhibiting kinase activity of c-Met in cells, as well as modulating its expression. The applications of his inventions extend to the prevention and treatment of cell proliferative disorders, including various types of cancers. Additionally, the patents include formulations of pharmaceutical compositions that utilize these compounds, opening new avenues for therapeutic development.
Career Highlights
Ehab Khalil's career includes significant positions at prominent companies such as Janssen Pharmaceutica and 3-Dimensional Pharmaceuticals, Inc. His work in these organizations has undoubtedly influenced advancements in pharmaceutical research and development, showcasing his commitment to improving healthcare through innovative solutions.
Collaborations
Throughout his career, Ehab has had the privilege of collaborating with talented individuals such as Heather Rae Hufnagel and Kristi A Leonard. These partnerships have contributed to the rich tapestry of innovation within his projects, fostering an environment of creativity and scientific exploration.
Conclusion
In conclusion, Ehab Khalil stands as a beacon of innovation in the field of pharmaceutical technology. With his extensive portfolio of patents and collaborative spirit, he continues to make significant strides in the treatment of diseases related to c-Met. His ongoing contributions promise to enhance the efficacy of therapeutic strategies and improve patient outcomes in the future.